Actively Recruiting

Age: 18Years - 70Years
All Genders
NCT07118631

Clinical Study on Emergency Treatment of Cerebral Arteriovenous Malformation Bleeding

Led by Beijing Tiantan Hospital · Updated on 2025-08-12

162

Participants Needed

1

Research Sites

147 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Cerebral arteriovenous malformation (AVM) is the leading cause of brain hemorrhage in young adults, characterized by sudden onset and rapid progression. The hybrid neurosurgical operating room is a diagnostic and therapeutic platform that integrates neurointervention and microneurosurgery, offering advantages such as one-stop rapid treatment and multimodal therapeutic approaches. This study aims to focus on patients with acute cerebral AVM-related hemorrhage through a multicenter, prospective, registry-based research approach. In the hybrid neurosurgical operating room, emergency cerebral angiography, neurointerventional embolization, microsurgical resection of the vascular malformation, or minimally invasive hematoma evacuation will be performed to explore the indications and advantages of the hybrid neurosurgical operating platform in emergency AVM hemorrhage management. The study seeks to establish standardized diagnostic and treatment protocols and operational workflows for emergency AVM hemorrhage management in the hybrid operating room. Through continuous quality improvement, the study aims to further reduce patient morbidity and mortality. This research will not only enhance the diagnostic and therapeutic level of cerebral AVM-related hemorrhage and improve patient outcomes but also effectively reduce medical costs and societal burdens.

CONDITIONS

Official Title

Clinical Study on Emergency Treatment of Cerebral Arteriovenous Malformation Bleeding

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Head CT confirmed cerebral hemorrhage requiring emergency surgery
  • Head CTA indicating possible cerebral arteriovenous malformation lesion
  • Spetzler-Martin classification 1 to 4 for cerebral AVM
  • Age between 18 and 70 years
  • Systemic condition able to tolerate surgery
  • Agreement to surgical treatment and signed informed consent
Not Eligible

You will not qualify if you...

  • Consciousness disorder caused by serious underlying diseases
  • Refusal of surgery by patient or family members
  • Perinatal or pregnancy status

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Beijing Tiantan Hospital, Capital Medical University

Beijing, China, 100070

Actively Recruiting

Loading map...

Research Team

Y

Yuming Jiao, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Clinical Study on Emergency Treatment of Cerebral Arteriovenous Malformation Bleeding | DecenTrialz